• Neurontin was introduced by Warner-Lambert in 1994 to help preserve that company's epilepsy franchise.

    FORBES: Pfizer's Disappointing Victory

  • Neurontin, another Pfizer drug from the same time period, should serve as a reminder of this.

    FORBES: Fear, Apathy, And Bureaucracy: Why We Won't Have Another Lipitor

  • Pfizer has long said a patent would protect Neurontin until 2017, but generic companies have been undeterred.

    FORBES: Pfizer's Disappointing Victory

  • But pregabalin, after several regulatory delays, is likely to have broader approval for treating pain than Neurontin does.

    FORBES: Generic Competition Won't Fell Pfizer

  • Already, Pfizer's sales are flat because of generic competition for products like antibiotic Zithromax and nerve-pain drug Neurontin.

    FORBES: Magazine Article

  • Aaron Kesselheim of Harvard University tracked sales of Neurontin, a drug approved for epilepsy but prescribed for much more.

    ECONOMIST: Johnson & Johnson

  • Several generic companies are trying to bring copycat versions of Neurontin to market.

    FORBES: Magazine Article

  • Originally an epilepsy medication, Neurontin wound up being used mostly for treating other disorders, particularly pain caused by nerve damage.

    FORBES: When Doctors Go Off-Label

  • Lyrica, an improved version of the off-patent Neurontin, was initially delayed for several years at the U.S. Food and Drug Administration.

    FORBES: Pfizer's New Blockbuster Drug

  • The latest: Unlike Neurontin, Lyrica has been labeled as a controlled substance.

    FORBES

  • Krensavage says the company's profits may suffer significantly from introductions of rival generic versions of Neurontin, an antiseizure drug, and Augmentin, an antibiotic.

    FORBES: Drug Test

  • Lyrica was supposed to be a follow-up to Neurontin, an epilepsy drug that eventually hit peak annual sales 30-times greater than initial expectations.

    FORBES: Pfizer's Disappointing Victory

  • Neurontin, for epilepsy and neuropathic pain, Zithromax, for bacterial infections, Zyrtec, for allergies, and Viagra, for sexual dysfunction, all grew at double-digit rates.

    FORBES: Pfizer's Next Move

  • Although Neurontin was originally approved as an epilepsy drug, doctors often prescribed it for pain due to nerve damage from diabetes or other illnesses.

    FORBES: Generic Competition Won't Fell Pfizer

  • Pfizer (nyse: PFE - news - people ), for instance, has faced investigations and fines related to marketing of its Neurontin.

    FORBES: When Doctors Go Off-Label

  • Generic drug makers are fighting in court to sell their copycat versions of Neurontin, but it's still possible that pregabalin could reach the market first.

    FORBES: Generic Competition Won't Fell Pfizer

  • But some epilepsy medicines, including Neurontin from Pfizer and Gabitril from Cephalon (nasdaq: CEPH - news - people ), may also help slow wave sleep.

    FORBES: Sleep On Demand

  • For instance, Pfizer 's (nyse: PFE - news - people ) Neurontin, initially an epilepsy drug, became widely used for pain caused by nerve damage and anxiety.

    FORBES: Silver Lining In Drug Disclosure

  • McKinnell said that the bad results for 2005 were precipitated by the problems with the Cox-2 inhibitors, which have faced safety concerns, and the surprise loss of a patent protecting Neurontin, a blockbuster for epilepsy and neuropathic pain.

    FORBES: Pfizer's Tough Transition

  • Pfizer said that its Lyrica, a follow-up to the blockbuster epilepsy and nerve pain drug Neurontin, has been associated with a few cases of muscle weakness, but that the company is still expecting U.S. Food and Drug Administration approval for the long-delayed drug.

    FORBES: Pfizer's Tough Sell

  • Instead, doctors found that Neurontin helped with many other ailments, particularly pain caused by nerve damage due to conditions like shingles and diabetes. (This is called neuropathic pain.) That put Warner-Lambert in a bind, because it could not promote the drug for these unapproved uses.

    FORBES

  • Indeed, in the past, Pfizer (nyse: PFE - news - people ), the world's biggest drug company, owed much of the sales volume of its epilepsy medicine Neurontin to off-label use for pain and for disorders ranging from panic to bipolar disorder.

    FORBES: InterMune Gets Around The FDA

  • The First Circuit Court of Appeals, in a decision yesterday, ruled that a lower court erred when it refused to allow Aetna to sue Pfizer over what it called a racketeering conspiracy to induce physicians to prescribe Neurontin for off-label uses like treating bipolar disorder.

    FORBES: Pfizer Loses As Appeals Court Allows Off-Label Marketing Case To Proceed

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定